Robin Gasiorowski

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières et al. · Journal of Clinical Oncology · 2022 · 484 citations · Full text

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 245 citations

Interim Analysis, Lymphoid Neoplasia, Medicine +8

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Franck Morschhauser, Pierre Feugier, Ian W. Flinn et al. · Blood · 2020 · 158 citations · Full text

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Catherine Thiéblemont, Yasmin Karimi, Hervé Ghesquières et al. · Leukemia · 2024 · 87 citations · Full text

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the <scp>COVID</scp>‐19 pandemic

Pietro R Di Ciaccio, Georgia McCaughan, Judith Trotman et al. · Internal Medicine Journal · 2020 · 42 citations · Full text